We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+6.22%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.54B
AUM Growth
+$215M
Cap. Flow
-$203M
Cap. Flow %
-2.69%
Top 10 Hldgs %
62.44%
Holding
434
New
139
Increased
87
Reduced
85
Closed
95

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
INCY icon
Incyte
INCY
+$117M
3
GRFS
Grifois
GRFS
+$51.9M
4
HUM icon
Humana
HUM
+$47.4M
5
KO icon
Coca-Cola
KO
+$45.2M

Sector Composition

Rank Sector Weight
1 Healthcare 33.9%
2 Consumer Staples 5.54%
3 Consumer Discretionary 5.08%
4 Technology 3.55%
5 Communication Services 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IBIO icon
151
iBio
IBIO
$67.6M
$1.42M 0.02%
+350,877
New +$441K
PPBT
152
Purple Biotech
PPBT
$1.38M
$1.42M 0.02%
10,575
+1,164
+12% +$167K
BKNG icon
153
Booking.com
BKNG
$156B
$1.38M 0.02%
+9,500
New +$1.35M
SQSP
154
DELISTED
Squarespace, Inc.
SQSP
$1.35M 0.02%
+36,945
New +$1.2M
CTM icon
155
Castellum
CTM
$76.3M
$1.21M 0.02%
+4,655,987
New +$1.41M
EVAX
156
Evaxion A/S
EVAX
$25M
$1.17M 0.02%
+73,400
New +$1.76M
WKSP icon
157
Worksport
WKSP
$10.9M
$1.11M 0.01%
193,811
+23,111
+14% +$267K
GAP
158
The Gap Inc
GAP
$7.4B
$1.11M 0.01%
40,131
+1,125
+3% +$23.7K
VCNX
159
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$1.07M 0.01%
+145,000
New +$1.26M
HUBS icon
160
HubSpot
HUBS
$10B
$1.05M 0.01%
1,680
+610
+57% +$367K
BTAI icon
161
BioXcel Therapeutics
BTAI
$25.2M
$1.05M 0.01%
+23,186
New +$1.11M
XHB icon
162
State Street SPDR S&P Homebuilders ETF
XHB
$1.53B
$1.01M 0.01%
+9,084
New +$908K
HEPA
163
DELISTED
Hepion Pharmaceuticals
HEPA
$971K 0.01%
7,800
-560
-7% -$64.4K
COLM icon
164
Columbia Sportswear
COLM
$2.96B
$958K 0.01%
+11,800
New +$937K
WBA
165
DELISTED
Walgreens Boots Alliance
WBA
$952K 0.01%
+43,913
New +$976K
ALP
166
Alpha Compute
ALP
$4.3M
$938K 0.01%
83,294
-10,511
-11% -$158K
LULU icon
167
lululemon athletica
LULU
$14.2B
$931K 0.01%
2,382
+1,462
+159% +$676K
ZSQR
168
Z Squared Inc
ZSQR
$212M
$901K 0.01%
151,513
-24,487
-14% -$247K
MBRX icon
169
Moleculin Biotech
MBRX
$2.69M
$878K 0.01%
5,940
-2,613
-31% -$557K
DUOL icon
170
Duolingo
DUOL
$5.68B
$870K 0.01%
3,946
+1,996
+102% +$407K
DDS icon
171
Dillards
DDS
$9.68B
$851K 0.01%
+1,804
New +$739K
CANF
172
Can-Fite BioPharma American Depositary Shares
CANF
$7.52M
$850K 0.01%
19,140
+11,422
+148% +$477K
CVKD icon
173
Cadrenal Therapeutics
CVKD
$6.74M
$823K 0.01%
89,972
+62,353
+226% +$791K
AEO icon
174
American Eagle Outfitters
AEO
$2.98B
$800K 0.01%
+31,022
New +$689K
GOLF icon
175
Acushnet Holdings
GOLF
$5.62B
$729K 0.01%
11,051
+6,297
+132% +$408K

Similar funds

Armistice Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Armistice Capital held 434 positions worth $7.54B, up 2.9% from $7.33B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q1 2024 filing shows 139 new, 87 increased, 85 reduced and 95 closed positions. Its largest new stake was Cytokinetics: 1,525,688 shares worth $107M. The largest sale was Shockwave Medical, Inc. Common Stock, an estimated $88.4M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Armistice Capital's largest Q1 2024 buy was Cytokinetics: 1,525,688 shares worth $107M.
  • Armistice Capital added most to Incyte in Q1 2024, an estimated $117M increase.
  • Armistice Capital's biggest Q1 2024 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $88.4M.
  • Armistice Capital fully exited Jazz Pharmaceuticals in Q1 2024, selling an estimated $80.1M.
  • Armistice Capital's ten largest holdings make up 62% of its $7.54B portfolio in Q1 2024.
  • Armistice Capital opened 139 new positions and closed 95 in Q1 2024.
  • Armistice Capital's portfolio value rose 2.9% quarter-over-quarter to $7.54B.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.